JP2003516987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003516987A5 JP2003516987A5 JP2001544732A JP2001544732A JP2003516987A5 JP 2003516987 A5 JP2003516987 A5 JP 2003516987A5 JP 2001544732 A JP2001544732 A JP 2001544732A JP 2001544732 A JP2001544732 A JP 2001544732A JP 2003516987 A5 JP2003516987 A5 JP 2003516987A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- trifluoroacetate
- hydrochloride
- mammal
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 description 58
- 150000001875 compounds Chemical class 0.000 description 55
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 54
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 54
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 50
- 239000008194 pharmaceutical composition Substances 0.000 description 43
- 241000124008 Mammalia Species 0.000 description 41
- 239000000203 mixture Substances 0.000 description 39
- 239000003814 drug Substances 0.000 description 28
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 27
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 27
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 27
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 27
- 229940095064 tartrate Drugs 0.000 description 27
- 239000003937 drug carrier Substances 0.000 description 25
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 23
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 23
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 23
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 23
- 229940049920 malate Drugs 0.000 description 23
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 23
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 20
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- DETXZQGDWUJKMO-UHFFFAOYSA-N 2-hydroxymethanesulfonic acid Chemical compound OCS(O)(=O)=O DETXZQGDWUJKMO-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 101150012716 CDK1 gene Proteins 0.000 description 5
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 5
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 5
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 125000000547 substituted alkyl group Chemical group 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 150000001860 citric acid derivatives Chemical class 0.000 description 4
- ICIWUVCWSCSTAQ-UHFFFAOYSA-N iodic acid Chemical class OI(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-N 0.000 description 4
- 150000004701 malic acid derivatives Chemical class 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 4
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 101150053721 Cdk5 gene Proteins 0.000 description 3
- 101150090188 Cdk8 gene Proteins 0.000 description 3
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 3
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 101150112625 SSN3 gene Proteins 0.000 description 3
- 101100150415 Schizosaccharomyces pombe (strain 972 / ATCC 24843) srb10 gene Proteins 0.000 description 3
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000001342 alkaline earth metals Chemical class 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 229940072107 ascorbate Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 3
- 229940092714 benzenesulfonic acid Drugs 0.000 description 3
- 229940050390 benzoate Drugs 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 150000001642 boronic acid derivatives Chemical class 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 101150073031 cdk2 gene Proteins 0.000 description 3
- 101150059448 cdk7 gene Proteins 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000002823 nitrates Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 3
- 229960001860 salicylate Drugs 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 3
- USAKOZCUIYTREA-LLVKDONJSA-N (3r)-n-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)[C@H]1CNCCC1 USAKOZCUIYTREA-LLVKDONJSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- OUSFTKFNBAZUKL-UHFFFAOYSA-N N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000022605 chemotherapy-induced alopecia Diseases 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- USAKOZCUIYTREA-UHFFFAOYSA-N n-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CNCCC1 USAKOZCUIYTREA-UHFFFAOYSA-N 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- USAKOZCUIYTREA-NSHDSACASA-N (3s)-n-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)[C@@H]1CNCCC1 USAKOZCUIYTREA-NSHDSACASA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- NASKBLMGBFRGIF-UHFFFAOYSA-N n-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-(2-hydroxyethyl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCN(CCO)CC1 NASKBLMGBFRGIF-UHFFFAOYSA-N 0.000 description 1
- BMJRSDXYHRHHKI-UHFFFAOYSA-N n-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-cyclopropylpiperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCN(C2CC2)CC1 BMJRSDXYHRHHKI-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/464,511 | 1999-12-15 | ||
| US09/464,511 US6262096B1 (en) | 1997-11-12 | 1999-12-15 | Aminothiazole inhibitors of cyclin dependent kinases |
| US61662700A | 2000-07-26 | 2000-07-26 | |
| US09/616,627 | 2000-07-26 | ||
| PCT/US2000/033501 WO2001044242A1 (en) | 1999-12-15 | 2000-12-07 | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003516987A JP2003516987A (ja) | 2003-05-20 |
| JP2003516987A5 true JP2003516987A5 (enExample) | 2008-01-31 |
Family
ID=27041008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001544732A Withdrawn JP2003516987A (ja) | 1999-12-15 | 2000-12-07 | サイクリン依存性キナーゼのｎ−［５−［［［５−アルキル−２−オキサゾリル］メチル］チオ−２−チアゾリル］カルボキサミドインヒビター |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1240166B1 (enExample) |
| JP (1) | JP2003516987A (enExample) |
| KR (1) | KR100738132B1 (enExample) |
| CN (1) | CN1433416A (enExample) |
| AR (1) | AR026974A1 (enExample) |
| AT (1) | ATE289306T1 (enExample) |
| AU (1) | AU783719B2 (enExample) |
| BR (1) | BR0016424A (enExample) |
| CA (1) | CA2394552A1 (enExample) |
| CO (1) | CO5261565A1 (enExample) |
| CZ (1) | CZ20022015A3 (enExample) |
| DE (1) | DE60018205T2 (enExample) |
| DK (1) | DK1240166T3 (enExample) |
| EG (1) | EG24168A (enExample) |
| ES (1) | ES2236034T3 (enExample) |
| HK (1) | HK1049661B (enExample) |
| HU (1) | HUP0301032A3 (enExample) |
| IL (2) | IL149755A0 (enExample) |
| MX (1) | MXPA02005870A (enExample) |
| MY (1) | MY125768A (enExample) |
| NO (1) | NO323726B1 (enExample) |
| NZ (1) | NZ519120A (enExample) |
| PE (1) | PE20011026A1 (enExample) |
| PL (1) | PL364921A1 (enExample) |
| PT (1) | PT1240166E (enExample) |
| RU (1) | RU2002119016A (enExample) |
| TW (1) | TWI273103B (enExample) |
| UY (1) | UY26481A1 (enExample) |
| WO (1) | WO2001044242A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6414156B2 (en) * | 1998-10-21 | 2002-07-02 | Bristol-Myers Squibb Company | Process for preparing azacycloalkanoylaminothiazoles |
| US6392053B2 (en) | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
| US6515004B1 (en) | 1999-12-15 | 2003-02-04 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| WO2002010162A1 (en) * | 2000-07-26 | 2002-02-07 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6638926B2 (en) | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| CA2432799C (en) | 2000-12-21 | 2008-08-19 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| PT1532145E (pt) | 2002-08-02 | 2007-01-31 | Vertex Pharma | Composiçoes de pirazole úteis como inibidores de gsk-3 |
| US7392929B1 (en) | 2004-07-26 | 2008-07-01 | Zephyros, Inc. | Weldable synthetic material |
| WO2006077428A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
| DE102005008310A1 (de) * | 2005-02-17 | 2006-08-24 | Schering Ag | Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle |
| WO2007056163A2 (en) | 2005-11-03 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| JP5528807B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8236128B2 (en) | 2006-10-26 | 2012-08-07 | Zephyros, Inc. | Adhesive materials, adhesive parts formed therewith and their uses |
| WO2008063933A2 (en) * | 2006-11-10 | 2008-05-29 | Massachusetts Institute Of Technology | Pak modulators |
| WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
| AU2010343102B2 (en) | 2009-12-29 | 2016-03-24 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| CA2972239A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| JP7590185B2 (ja) | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
-
2000
- 2000-11-16 MY MYPI20005385A patent/MY125768A/en unknown
- 2000-12-07 HK HK03100935.5A patent/HK1049661B/en not_active IP Right Cessation
- 2000-12-07 CA CA002394552A patent/CA2394552A1/en not_active Abandoned
- 2000-12-07 MX MXPA02005870A patent/MXPA02005870A/es active IP Right Grant
- 2000-12-07 JP JP2001544732A patent/JP2003516987A/ja not_active Withdrawn
- 2000-12-07 AU AU27264/01A patent/AU783719B2/en not_active Ceased
- 2000-12-07 PT PT00990204T patent/PT1240166E/pt unknown
- 2000-12-07 EP EP00990204A patent/EP1240166B1/en not_active Expired - Lifetime
- 2000-12-07 NZ NZ519120A patent/NZ519120A/en unknown
- 2000-12-07 AT AT00990204T patent/ATE289306T1/de not_active IP Right Cessation
- 2000-12-07 BR BR0016424-0A patent/BR0016424A/pt not_active Application Discontinuation
- 2000-12-07 DE DE60018205T patent/DE60018205T2/de not_active Expired - Fee Related
- 2000-12-07 CZ CZ20022015A patent/CZ20022015A3/cs unknown
- 2000-12-07 ES ES00990204T patent/ES2236034T3/es not_active Expired - Lifetime
- 2000-12-07 IL IL14975500A patent/IL149755A0/xx unknown
- 2000-12-07 RU RU2002119016/04A patent/RU2002119016A/ru unknown
- 2000-12-07 PL PL00364921A patent/PL364921A1/xx not_active Application Discontinuation
- 2000-12-07 WO PCT/US2000/033501 patent/WO2001044242A1/en not_active Ceased
- 2000-12-07 CN CN00818900A patent/CN1433416A/zh active Pending
- 2000-12-07 KR KR1020027007615A patent/KR100738132B1/ko not_active Expired - Fee Related
- 2000-12-07 DK DK00990204T patent/DK1240166T3/da active
- 2000-12-07 HU HU0301032A patent/HUP0301032A3/hu unknown
- 2000-12-09 EG EG20001523A patent/EG24168A/xx active
- 2000-12-14 UY UY26481A patent/UY26481A1/es not_active Application Discontinuation
- 2000-12-14 TW TW089126788A patent/TWI273103B/zh not_active IP Right Cessation
- 2000-12-14 CO CO00095237A patent/CO5261565A1/es not_active Application Discontinuation
- 2000-12-15 AR ARP000106680A patent/AR026974A1/es unknown
- 2000-12-15 PE PE2000001347A patent/PE20011026A1/es not_active Application Discontinuation
-
2002
- 2002-05-20 IL IL149755A patent/IL149755A/en active IP Right Grant
- 2002-06-13 NO NO20022817A patent/NO323726B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003516987A5 (enExample) | ||
| AU2014272776B2 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| AU2014372166B2 (en) | Pharmaceutical combinations | |
| JP6193922B2 (ja) | ハロアルキルヘテロアリールベンズアミド化合物 | |
| RU2331648C2 (ru) | Соединения тиенопиримидина и их применение | |
| US7019011B2 (en) | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | |
| US20110312992A1 (en) | Inhibitors of C-Kit and Uses Thereof | |
| JP2018531983A (ja) | タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法 | |
| TWI629276B (zh) | 咪唑并嗒化合物 | |
| TWI786078B (zh) | 金屬酶抑制劑化合物、抑制金屬酶活性之方法、使用金屬酶抑制劑化合物的方法及醫藥組成物 | |
| EP4233834A2 (en) | Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks | |
| TW201429957A (zh) | 用於激酶調節及其適應症之化合物及方法 | |
| RU2002119016A (ru) | N-[5-[[[5-алкил-2-оксазолил]метил]тио]-2-тиазолил]карбоксамидные ингибиторы циклин-зависимых киназ | |
| JP2002528497A (ja) | 偏頭痛の治療のための５ｈｔ１受容体アゴニスト及びメトクロプラミド | |
| JP2008534552A (ja) | 血栓症治療用の新規な医薬組成物 | |
| CN1444584A (zh) | 依赖细胞周期蛋白的激酶的n－[5－[[[5－烷基－2－噁唑基]甲基]硫代]－2－噻唑基]甲酰胺抑制剂 | |
| WO2021064141A1 (en) | Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b | |
| CN110325523B (zh) | 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺 | |
| WO2018210729A1 (en) | Aromatic sulfonamide derivatives as antagonists or negative allosteric modulators of p2x4 receptor | |
| AU2011323594B2 (en) | Pharmaceutical compositions | |
| KR20200015595A (ko) | 화합물 | |
| HK40074977A (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| HK40074980A (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| EA048371B1 (ru) | Гетероциклические производные, фармацевтические композиции и их применение при лечении рака или для улучшения состояния при раке | |
| RU2003103707A (ru) | N-[5-[[[5-алкил-2-оксазолил]метил]тио)-2-тиазолил]карбоксамидные ингибиторы циклинзависимых киназ |